Australia's Pharmaxis Breathing Easier Following U.S. FDA Advisory Committee Recommendation For Bronchial Test Aridol
This article was originally published in PharmAsia News
Executive Summary
PERTH, Australia - Sydney-based Pharmaxis is breathing easier following a positive recommendation from U.S. FDA's Pulmonary-Allergy Drugs Advisory Committee Nov. 20 for approval of its bronchial test Aridol
You may also be interested in...
Australian Pharmaxis Reports Positive Results From Phase III Bronchitol Cystic Fibrosis Study
PERTH, Australia - Sydney-based Pharmaxis announced Dec. 2 positive headline results from its second Phase III trial of Bronchitol (mannitol) in people with cystic fibrosis
Australian Pharmaxis Reports Positive Results From Phase III Bronchitol Cystic Fibrosis Study
PERTH, Australia - Sydney-based Pharmaxis announced Dec. 2 positive headline results from its second Phase III trial of Bronchitol (mannitol) in people with cystic fibrosis
Sydney-Based Pharmaxis Gets FDA Green Light On Bronchitol SPA
PERTH, Australia - Sydney-based Pharmaxis and the U.S. FDA reached an agreement on a Phase III registration trial of Bronchitol (mannitol) for treatment of bronchiectasis through the special protocol assessment process, which will form the basis of the company's efficacy claim, PharmAxis announced June 20